213 related articles for article (PubMed ID: 30913016)
1. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
6. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K
Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105
[TBL] [Abstract][Full Text] [Related]
7. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
8. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; DeSouza P; Yang T; Niles N
Thyroid; 2018 Mar; 28(3):349-361. PubMed ID: 29455638
[TBL] [Abstract][Full Text] [Related]
9. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
10. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Cantara S; Bertelli E; Occhini R; Regoli M; Brilli L; Pacini F; Castagna MG; Toti P
Endocrine; 2019 Apr; 64(1):122-129. PubMed ID: 30762153
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract][Full Text] [Related]
12. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Wang H; Zhang Z; Yan Z; Ma S
Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
[TBL] [Abstract][Full Text] [Related]
13. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
[TBL] [Abstract][Full Text] [Related]
14. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
[TBL] [Abstract][Full Text] [Related]
15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
16. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
[TBL] [Abstract][Full Text] [Related]
17. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
[TBL] [Abstract][Full Text] [Related]
18. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P
Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817
[TBL] [Abstract][Full Text] [Related]
19. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression and Ultrasound Characteristics in Papillary Thyroid Carcinoma and Its Effect on Recurrence.
Li R; Li M; Sun B; Qi M; Peng C; Li H; Zheng S; Liu Q; Jiang C
In Vivo; 2023; 37(6):2820-2828. PubMed ID: 37905619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
